Get the Stockscreener App
0.87
0.35%
0.003
After Hours:
.87
Calcimedica Inc stock is traded at $0.87, with a volume of 51,368.
It is up +0.35% in the last 24 hours and up +32.40% over the past month.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.
See More
Previous Close:
$0.867
Open:
$0.9
24h Volume:
51,368
Relative Volume:
0.21
Market Cap:
$13.74M
Revenue:
-
Net Income/Loss:
$-19.54M
P/E Ratio:
-0.6656
EPS:
-1.3071
Net Cash Flow:
$-21.18M
1W Performance:
-9.19%
1M Performance:
+32.40%
6M Performance:
-81.21%
1Y Performance:
-49.42%
1-Day Range:
$0.8605
$0.9312
1-Week Range:
$0.8438
$1.015
52-Week Range:
$0.4606
$7.20
Calcimedica Inc Stock (CALC) Company Profile
Name
Calcimedica Inc
Sector
Industry
Phone
858-952-5500
Address
505 COAST BOULEVARD SOUTH, LA JOLLA
Compare CALC vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CALC
Calcimedica Inc
|
0.87 | 13.70M | 0 | -19.54M | -21.18M | -1.3071 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Calcimedica Inc Stock (CALC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-26 | Downgrade | H.C. Wainwright | Buy → Neutral |
Calcimedica Inc Stock (CALC) Latest News
CalciMedica (CALC) Slips 2.75% as Stock Tests Key Support LevelsVolatility Breakout Picks - newsline.com
CALC Q1 2026 Earnings: Surprising Profitability Amid No RevenueHigh Growth Earnings - newsline.com
CALC Stock Chart | CALCIMEDICA INC (NASDAQ:CALC) - ChartMill
CALC Q1 2026 Earnings: Surprise Profit Amid Pre-Revenue Pipeline ProgressEPS Consistency Score - newsline.com
CalciMedica (CALC) Slips 6%: Support Level Holds Key to RecoveryCTA Positioning - newsline.com
CalciMedica (CALC) Faces Selling Pressure Near Support as Biotech Uncertainty PersistsInitial Balance - newsline.com
CALC Q1 2026 Earnings: Surprising Profit on a Per‑Share Basis, Yet Shares DeclineOne-Time Loss Impact - thelegaladvocate.com
CalciMedica (CALC) Edges Lower, Approaching Critical Support at $0.70PCR Mean Reversion - The Legal Advocate
CalciMedica (CALC) Holds Near Support as Price Movement Remains MinimalTotal Put Call - newsline.com
Number of shareholders of CalciMedica, Inc. – NASDAQ:CALC - TradingView
CALC Q1 2026 Earnings: EPS Misses Estimates Amid Ongoing Clinical-Stage InvestmentsRevenue Guidance Update - The Legal Advocate
CalciMedica (CALC) Rises +4.47%: Technicals vs Fundamentals — Which Wins? 2026-05-21Trading Community - Newser
CalciMedica (CALC) reporting person holds 0 shares after amendment - Stock Titan
CalciMedica, Inc. (CALC) Fundamental Analysis - Meyka
Analysts Are Bullish on These Healthcare Stocks: Meiragtx Holdings (MGTX), CalciMedica (CALC) - The Globe and Mail
CalciMedica (CALC) Q4 2025 Disappoints — EPS $-0.73 Below $-0.42 ViewsInvestment Community - Newser
Analysts Have Conflicting Sentiments on These Healthcare Companies: West Pharmaceutical Services (WST), CalciMedica (CALC) and Tyra Bioscience (TYRA) - The Globe and Mail
[10-Q] CalciMedica, Inc. Quarterly Earnings Report - Stock Titan
CalciMedica Releases Q1 2026 Financial Results - AlphaStreet
CalciMedica Reports Q1 2026 Financial Results, Advances Auxora and CM5480 Clinical Programs - Minichart
TradingKey - TradingKey
CalciMedica posts Q1 profit on higher other income, lower expenses - TradingView
CalciMedica (NASDAQ: CALC) swings to Q1 profit as expenses decline - Stock Titan
CalciMedica, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates - PR Newswire
[SCHEDULE 13G/A] CalciMedica, Inc. Amended Passive Investment Disclosure - Stock Titan
CalciMedica Inc expected to post a loss of 28 cents a shareEarnings Preview - TradingView
CalciMedica (CALC) details 2025 executive pay, ownership and $20.4M raise - Stock Titan
CALC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Is CalciMedica (CALC) stock a long-term winner | Q4 2025: Earnings UnderperformMarket Expert Watchlist - Newser
CalciMedica (CALC) Stock: Sentiment Analysis | Q4 2025: Below ExpectationsSector Outperform - Xã Châu Thành
CALC Options Chain — NASDAQ:CALC - TradingView
MACD Signal: Does CalciMedica Inc outperform in volatile marketsMarket Sentiment Report & AI Enhanced Trading Alerts - baoquankhu1.vn
Profit Review: Does CalciMedica Inc have consistent dividend growth2026 Growth vs Value & Accurate Technical Buy Alerts - baoquankhu1.vn
EPS Watch: Is CalciMedica Inc attractive for institutional investorsPortfolio Gains Summary & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Jobs Data: Is CalciMedica Inc exposed to currency risks2026 PostEarnings & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
CalciMedica (NASDAQ: CALC) grants CSO 65,124 options at $0.585 - Stock Titan
CalciMedica (CALC) CFO receives 67,728 stock options at $0.585 strike price - Stock Titan
CalciMedica (CALC) grants 65,124 stock options to President and COO - Stock Titan
Earnings Risk: Does CalciMedica Inc meet Warren Buffetts criteriaMarket Growth Review & Fast Momentum Entry Tips - baoquankhu1.vn
CALC PE Ratio & Valuation, Is CALC Overvalued - Intellectia AI
CALC Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
CalciMedica (CALC) price target decreased by 24.39% to 10.54 - MSN
If You Invested $1,000 in CALCIMEDICA INC (CALC) - Stock Titan
Revenue Check: Does CalciMedica Inc meet Warren Buffetts criteria2026 Drop Watch & Detailed Earnings Play Alerts - baoquankhu1.vn
Big Picture: Does CalciMedica Inc meet Warren Buffetts criteriaShare Buyback & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
CalciMedica receives Nasdaq delisting notices for market value and bid price - Investing.com Australia
CalciMedica Receives Nasdaq Deficiency Notices on Listing Standards - TipRanks
CalciMedica Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Calcimedica Inc Stock (CALC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):